Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The ...
2d
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
Issued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established ...
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the ...
Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.
Mesoblast (NASDAQ:MESO) executives highlighted strong early commercial momentum for its cell therapy Ryoncil and outlined ...
Detailed price information for Mesoblast Ltd Ord (MEOBF) from The Globe and Mail including charting and trades.
Mesoblast’s CEO will “lead by example” and take a 30% pay cut as the biotech continues to reel from another FDA rejection of its off-the-shelf cell therapy. The Australian company had “anticipated ...
Mesoblast recently reported half-year 2026 results showing revenue of US$51.34 million versus US$3.16 million a year earlier, with net loss narrowing to US$40.16 million, and issued full‑year 2026 ...
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...
Mesoblast focuses on therapies to treat autoimmune disorders. The company's resubmission of Ryoncil was given a Complete Response Letter by the FDA. The company will have a trial of Ryoncil on adults ...
Several analysts have recently downgraded their positions on the pharmaceutical stock. Mesoblast focuses on therapies derived from the cells of the bone marrow from healthy donors. The company lost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results